Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Pharmacokinetics And Safety Of A Raltegravir-Containing Regimen In Children Aged 4 Weeks To 2 Years Living With Human Immunodeficiency Virus And Receiving Rifampin For Tuberculosis

Paul Krogstad,Pearl Samson,Edward P Acosta,Jack Moye,Ellen Townley,Sarah Bradford,Emily Brown,Kayla Denson,Bobbie Graham,Laura Hovind,Thucuma Sise,Hedy Teppler,Sisinyana Ruth Mathiba,Lee Fairlie,Jana L Winckler,Gretchen Slade,Tammy Meyers

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY（2021）

Cited 8|Views57
No score
Abstract
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.
More
Translated text
Key words
antiretroviral therapy, drug interactions, pediatrics, rifampin, tuberculosis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined